Skip to main content

Drug Interactions between digitoxin and eravacycline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

digitoxin eravacycline

Applies to: digitoxin and eravacycline

MONITOR CLOSELY: Tetracyclines may increase serum levels of orally administered digoxin by preventing specific bacteria, present in the lower intestine, from inactivating digoxin. About 10% of the population use this mechanism to metabolize digoxin. When digoxin was administered with tetracycline in a pharmacokinetic study done in adults, the digoxin serum concentration increased by 100%. Currently there is no data demonstrating the effects of other tetracyclines on digoxin levels. The risk of an interaction may be less with digoxin solution in capsules because absorption occurs in the upper GI tract.

MANAGEMENT: Close clinical monitoring of digoxin serum concentration as well as signs or symptoms of digoxin toxicity are recommended when antibiotic therapy is initiated or discontinued. It is advisable to obtain a baseline digoxin level prior to initiating concomitant therapy. Some authorities recommend reducing the digoxin dose by around 30% to 50% or modifying the dosing frequency, followed by additional monitoring. Patients should be advised to notify their physicians if they experience nausea, anorexia, fatigue, visual changes, slow pulse, and/or irregular heartbeats.

References (9)
  1. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR (1981) "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med, 305, p. 789-94
  2. Lindenbaum J, Tse-Eng D, Butler VP, Rund DG (1981) "Urinary excretion of reduced metabolites of digoxin." Am J Med, 71, p. 67-74
  3. Rodin SM, Johnson BF (1988) "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet, 15, p. 227-44
  4. (2019) "Product Information. Digoxin (digoxin)." Amneal Pharmaceuticals LLC
  5. (2022) "Product Information. PMS-Digoxin (digoxin)." Pharmascience Inc
  6. (2022) "Product Information. Digoxin (digoxin)." Aspen Pharma Trading Ltd
  7. (2020) "Product Information. Sigmaxin (digoxin)." (Obsolete) Aspen Pharma Pty Ltd
  8. MacLeod-Glover N, Mink M, Yarema M, Chuang R (2016) "Digoxin toxicity: case for retiring its use in elderly patients?" Can Fam Physician, 62, p. 223-8
  9. Zhanel GG, cheung d, Adam H, et al. (2016) "Review of eravacycline, a novel fluorocycline antibacterial agent." Drugs, 76, p. 567-88

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.